PI-RADS 4和5分靶点的磁共振引导下前列腺穿刺活检:单中心经验
回顾性分析2012至2020年246例患者共277个PI-RADS 4和5分靶点的MRI引导下穿刺活检,总体前列腺癌检出率80.5%(按患者)和78%(按靶点),临床显著前列腺癌检出率63%;PI-RADS 5分靶点检出率92%高于PI-RADS 4分的68%(p<0.001),严重并发症发生率1.2%。
要点
- PI-RADS 5分靶点前列腺癌检出率92%,高于PI-RADS 4分的68%(p<0.001)。
- 初次穿刺组临床显著前列腺癌检出率66%(132/200),二次穿刺组50%(23/46),p<0.001。
- 穿刺与根治标本Gleason评分一致:27.2%升级、8.6%降级。
核心结论
- MRI引导下穿刺活检在初次和二次穿刺人群中均有较高的临床显著前列腺癌检出率;穿刺阳性针数、阳性针中癌占比及Gleason评分与根治标本的一致性均令人满意。
研究设计与样本
- 回顾性研究,纳入2012至2020年本机构接受MRI引导下穿刺活检的246例患者共277个PI-RADS 4和5分靶点,平均年龄65.7岁,前列腺特异性抗原中位值7.75 ng/mL;其中81例接受根治性前列腺切除术并纳入Gleason评分一致性分析。
诊断标准与关键数值
- 总体前列腺癌检出率按患者80.5%(198/246)、按靶点78%(216/277);初次穿刺组83.5%、二次穿刺组67.4%;临床显著前列腺癌总体63%,初次穿刺组66%(132/200)、二次穿刺组50%(23/46)(p<0.001);PI-RADS 4分靶点检出率68%、PI-RADS 5分靶点92%(p<0.001);根治标本对照中27.2%患者升级、8.6%患者降级。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine the diagnostic yield of magnetic resonance imaging (MRI) guided in-bore biopsy in patients with high likelihood multiparametric MRI (mpMRI) findings, regarding overall and clinically significant prostate cancer (csPCa) detection rates and concordance of biopsy and radical prostatectomy (RP) Gleason scores (GS).
METHODS: This retrospective study consisted of 277 Prostate Imaging Reporting and Data System (PI-RADS) assessment category 4 and 5 targets in 246 patients (mean age, 65.7 years; median prostate specific antigen value, 7.75 ng/mL) who had undergone in-bore biopsy at our institution between 2012 and 2020. Eighty-one patients who underwent RP were eligible for the concordance analysis of biopsy and RP specimen GS.
RESULTS: Overall PCa detection rates were 80.5 % per patient (198/246) and 78 % per target (216/277) and 83.5 % and 67.4 % in primary (biopsy naive) and secondary (at least one negative prior biopsy) settings. csPCa was found in 63 % overall, 66 % of patients (132/200) in the primary, and 50 % of patients (23/46) in the secondary biopsy settings (p < 0.001). The prostate cancer detection rate was 68 % and 92 % in PI-RADS 4 and 5, respectively (p < 0.001). In the radical prostatectomy subcohort, 27.2 % of patients were upgraded, 8.6 % of patients were downgraded from needle biopsy. Significant complications occurred in 1.2 % of patients.
CONCLUSIONS: MRI-guided in-bore prostate biopsy has a high detection rate of csPCa in primary and secondary biopsy cohorts. Biopsy results were satisfactory in terms of the number of positive cores, cancer percentage in positive cores, and concordance of GS in needle biopsy and RP specimen.
引用
- Vural M, Coskun B, Kilic M, et al. In-bore MRI-guided prostate biopsy in a patient group with PI-RADS 4 and 5 targets: A single center experience. Eur J Radiol. 2021. PMID: 34091134. doi:10.1016/j.ejrad.2021.109785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。